Clinical trials: Antipsychotic Agents
Schizophrenia
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
- Trial name
- NCT01908192
- Testing
- NaBen®
- Where
- 23 sites in United States, Taiwan
- Volunteers
- 60 people
- Sponsor
- SyneuRx International (Taiwan) Corp
DSM-IV Schizophrenia, Schizoaffective Disorder
Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents
The purpose of this study is to determine whether moderately ill Asian schizophrenic patients can be switched from their previous antipsychotic medication to aripiprazole with minimal adverse clinical consequences, and elucidate…
- Trial name
- NCT00545467
- Testing
- Aripiprazole
- Where
- Taiwan
- Volunteers
- 79 people
- Sponsor
- National Taiwan University Hospital
Diabetes, Obesity
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
This program aims to help Veterans who take antipsychotic medications lose weight. The investigators use a program based on the American Diabetes Association's "Diabetes Prevention Program," and the investigators have modified it…
- Conditions
- Diabetes, Obesity, Weight Gain
- Trial name
- MAMAO (NCT00344500)
- Testing
- Behavioral Weight Loss Program
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Shared Decision Making for Antipsychotic Medications
This study aims to provide an evidence-based shared decision making intervention for antipsychotic medications, the Antipsychotic Medication Decision Aid (APM-DA), for individuals experiencing early psychosis and provide, for the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05416658
- Testing
- The Antipsychotic Medication Decision Aid (APM-DA)
- Volunteers
- 120 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Antipsychotic Drug
Xingqi Daozhi Decoction for Antipsychotic-Induced Constipation
Antipsychotic medications are widely used to treat schizophrenia but may cause constipation, which can lead to abdominal discomfort, reduced quality of life, and poor treatment adherence.
- Trial name
- XQD-AIC (NCT07767526)
- Testing
- Xingqi Daozhi Decoction
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai Mental Health Center
Lurasidone Cardiotoxicity, Schizophrenia Patients
Effects of Lurasidone on Left Ventricle Systolic Functions
The goal of our study to learn if lurasidone molecule which is used on patients with schizophrenia or bipolar disorder has any cardiotoxic effect.
- Conditions
- Lurasidone Cardiotoxicity, Schizophrenia Patients, Bipolar Disorders
- Trial name
- Lurasidone (NCT06695676)
- Testing
- Global Longitudinal Strain
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Aydin Adnan Menderes University
Psychotic Disorders
Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting
Despite different pharmacological properties, the scientific evidence is inconclusive regarding which of the first-line second generation antipsychotics (SGAs) should be preferred for the individual patient suffering from…
- Trial name
- BPP (NCT00932529)
- Testing
- Olanzapine, Quetiapine, Risperidone
- Where
- Norway
- Volunteers
- 226 people
- Sponsor
- University of Bergen
Schizophrenia, Dyslipidemias
Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia
Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Vildagliptin can improve lipid levels in obese patients.
- Trial name
- NCT04761861
- Testing
- Vildagliptin 50 MG
- Where
- Egypt
- Sponsor
- Sadat City University
Bipolar I Disorder
Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients
The purpose of this study is to determine whether Bipolar I Disorder refractory treatment with Quetiapine monotherapy could be better potentiated with Lithium or Aripiprazole.
- Trial name
- ARIQUELI (NCT01710163)
- Testing
- Lithium, Aripiprazole
- Where
- 2 sites in Brazil
- Volunteers
- 50 people
- Sponsor
- University of Sao Paulo
Schizophrenia, Obesity
Metformin for Weight Loss in Schizophrenia
Study hypothesis is that patients on antipsychotics medication treated with metformin will show loss in weight and improved measures of glucose metabolism.
- Trial name
- NCT01177709
- Testing
- Metformin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Schizoaffective Disorder
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
The purpose of this study is to evaluate epidemiological characteristics of patients that experience relapse and need an admission in psychiatric acute units across Spain.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00399334
- Testing
- antipsychotic medications
- Volunteers
- 1,607 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Psychotic Disorders
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document both short-term, as well as long-term efficacy and safety of a long-acting injectable formulation of risperidone, in comparison with olanzapine for the treatment of patients with…
- Trial name
- NCT00236457
- Testing
- risperidone
- Volunteers
- 629 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Prodromal Schizophrenia, Psychotic Disorders
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to evaluate their ability to…
- Trial name
- NCT00169988
- Testing
- risperidone, sertraline-primary
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwell Health
Eating Disorders
Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa
This study will compare the effectiveness of two atypical antipsychotic medications, olanzapine and aripiprazole, in treating people with anorexia nervosa.
- Trial name
- NCT00685334
- Testing
- Olanzapine, Aripiprazole
- Where
- 2 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- New York State Psychiatric Institute
Psychosis, Remission
Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States
A 2-year prospective observational study comparing a group of patients in remitted states of psychosis undergoing guided antipsychotic dose reduction to a similar group of patients under maintenance antipsychotic treatment with…
- Trial name
- GDR (NCT03248180)
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- National Taiwan University Hospital
Dementia, Alzheimer Disease
Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of risperidone compared with placebo in the treatment of psychotic symptoms in patients with Alzheimer's disease
- Conditions
- Dementia, Alzheimer Disease, Mental Disorders
- Trial name
- NCT00034762
- Testing
- risperidone
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
High Triglycerides, Hypercholesterolemia
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication.
- Conditions
- High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00833976
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Psychotic Disorders
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine…
- Trial name
- NCT00216476
- Testing
- Aripiprazole, Risperidone Long Acting Injectable (LAI), Quetiapine
- Where
- 96 sites in Austria, Bulgaria and 22 more
- Volunteers
- 753 people
- Sponsor
- Janssen-Cilag International NV
Adolescent Depression
Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy
We hypothesize that antipsychotic induced hyperprolactinemia can decrease bone mineral accrual and decrease bone mineral content (BMC) in adolescents on antipsychotic therapy. Specifics Aims 1.
- Trial name
- NCT00399776
- Testing
- Bone Density Test
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Creighton University
Schizophrenia
A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia
The purpose of this study is to compare the efficacy and side effects of 6 commonly used antipsychotic drugs in the treatment of schizophrenia in a Chinese population.
- Trial name
- NCT02192723
- Testing
- Typical antipsychotic, Risperidone, Olanzapine
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Beijing HuiLongGuan Hospital